Navigation Links
Ring In the New Year With a Beautiful, Smooth Body
Date:3/12/2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... ... 29, 2015 , ... Assurex Health, a precision medicine company ... chronic pain conditions, has announced appointments to three key leadership roles, according to ... Vice President, Chief Financial Officer; Craig S. Lewis, Senior Vice President, Chief Marketing ...
(Date:6/29/2015)... ... June 29, 2015 , ... OR Manager announced Monday the ... and feel, as well as a redesigned logo and weekly eLetter. The website contains ... now more user-friendly and easier to navigate. , In addition to a refreshed ...
(Date:6/29/2015)... ... June 29, 2015 , ... ... from Kyowa Hakko Bio to French consumers. , The specialized eye health formulation ... stress caused by free radicals. In addition to Citicoline (Cognizin®), Biomacula provides necessary ...
(Date:6/29/2015)... Detroit, MI (PRWEB) , ... June 29, 2015 , ... ... offer Kybella™ injection to clients for the reduction of the double chin and redefining ... can cause a person to look much older and heavier causing the person distress ...
(Date:6/29/2015)... ST. PAUL, Minn. (PRWEB) , ... June 29, ... ... Air , an HVAC and plumbing company serving the Twin Cities area, provides ... encourages overall energy efficiency strategies for Twin Cities’ residents, addressing water conservation and ...
Breaking Medicine News(10 mins):Health News:Assurex Health Names Executives to Posts as CFO, CMO and VP/Clinical Operations 2Health News:Assurex Health Names Executives to Posts as CFO, CMO and VP/Clinical Operations 3Health News:OR Manager Launches New Website 2Health News:Bionops Laboratory Releases Biomacula, the First French Product with Citicoline (Cognizin®) 2Health News:Bionops Laboratory Releases Biomacula, the First French Product with Citicoline (Cognizin®) 3Health News:FACE Detroit Skin and Wellness Clinic Introduces Newly FDA Approved Kybella for the elimination of the Double Chin. 2Health News:Save Energy: MSP Plumbing, Heating & Air Endorses Efficiency 2Health News:Save Energy: MSP Plumbing, Heating & Air Endorses Efficiency 3
... studies demonstrated potential for pazopanib as a single,agent treatment for early stage ... In patients with stage I-III non-small cell lung cancer, 86 percent of ... reduction in tumor volume -- ... response rate of 35 percent. The median duration ...
... medication use in young children has been linked to ... leading the FDA to recommend against their use for ... about safety and efficacy, there has been little research ... very young children. Now, a new study from the ...
... offer help to millions of diabetics who are missed ... and diagnosis for diabetes is being called for to ... have the disease, a new report says. , "Approximately ... States are undiagnosed," study author Dr. Christopher Saudek, of ...
... on,Mental Illness (NAMI) will honor television journalist Jane ... illness at NAMI,s annual,convention in Orlando, Florida, June ... made the announcement today in,the NAMI Blog ... of,two television documentaries that NAMI was closely involved ...
... The American Lung,Association of Iowa will host a week long ... The camp is open for all children with,asthma from ages 7 ... kids with asthma to spend a week doing,things all other kids ... Association, "It is a chance for kids to learn that,having asthma ...
... tiny, specific pieces of non-coding genetic material known as ... of cancer to other parts of the body. Researchers ... and Ohio State University Medical Center in Columbus have ... miRNAs. The findings, reported at the annual meeting of ...
Cached Medicine News:Health News:NEW DATA FOR PAZOPANIB - GSK'S LATEST INVESTIGATIONAL ANTI-CANCER AGENT - SHOWS PROMISE ACROSS MULTIPLE CANCERS 2Health News:NEW DATA FOR PAZOPANIB - GSK'S LATEST INVESTIGATIONAL ANTI-CANCER AGENT - SHOWS PROMISE ACROSS MULTIPLE CANCERS 3Health News:NEW DATA FOR PAZOPANIB - GSK'S LATEST INVESTIGATIONAL ANTI-CANCER AGENT - SHOWS PROMISE ACROSS MULTIPLE CANCERS 4Health News:NEW DATA FOR PAZOPANIB - GSK'S LATEST INVESTIGATIONAL ANTI-CANCER AGENT - SHOWS PROMISE ACROSS MULTIPLE CANCERS 5Health News:NEW DATA FOR PAZOPANIB - GSK'S LATEST INVESTIGATIONAL ANTI-CANCER AGENT - SHOWS PROMISE ACROSS MULTIPLE CANCERS 6Health News:NEW DATA FOR PAZOPANIB - GSK'S LATEST INVESTIGATIONAL ANTI-CANCER AGENT - SHOWS PROMISE ACROSS MULTIPLE CANCERS 7Health News:NEW DATA FOR PAZOPANIB - GSK'S LATEST INVESTIGATIONAL ANTI-CANCER AGENT - SHOWS PROMISE ACROSS MULTIPLE CANCERS 8Health News:Study examines cold medication use in young children 2Health News:Panel Calls for Better Diabetes Screening 2Health News:NAMI Blog: PBS, MTV and Jane Pauley 2Health News:Jefferson, Ohio State team find gene signature profile for metastasis 2
(Date:6/29/2015)... Calif. , June 29, 2015 /PRNewswire/ ... of advanced visual prosthetic devices for the ... announced the publication of "Long-Term (60-month) Results ... Safety Outcomes Stratified by Age in Patients ... Clinical Ophthalmology . The 5-year data show ...
(Date:6/29/2015)... 29, 2015 /PRNewswire/-- CytRx Corporation (NASDAQ: CYTR ), ... today announced the presentation of interim results from its ... and safety of aldoxorubicin for the treatment of Kaposi,s ... presented on Wednesday, July 1, 2015 during a poster ... Herpesvirus (KSHV) and Related Agents in Hollywood, ...
(Date:6/29/2015)... , June 29, 2015  The automotive ... features to cars on the basis of consumer ... industry is now on the verge of integrating ... While automotive HWW non-critical features such as reconfigurable ... present in 30 to 40 percent of all ...
Breaking Medicine Technology:Five-Year Data Demonstrates Long Term Effectiveness and Safety of VisionCare's Telescope Implant for Macular Degeneration in Patients 65 Years and Older 2Five-Year Data Demonstrates Long Term Effectiveness and Safety of VisionCare's Telescope Implant for Macular Degeneration in Patients 65 Years and Older 3Five-Year Data Demonstrates Long Term Effectiveness and Safety of VisionCare's Telescope Implant for Macular Degeneration in Patients 65 Years and Older 4Five-Year Data Demonstrates Long Term Effectiveness and Safety of VisionCare's Telescope Implant for Macular Degeneration in Patients 65 Years and Older 5CytRx Announces Presentation of Interim Phase 2 Data for Aldoxorubicin for HIV-Related Kaposi's Sarcoma 2CytRx Announces Presentation of Interim Phase 2 Data for Aldoxorubicin for HIV-Related Kaposi's Sarcoma 3CytRx Announces Presentation of Interim Phase 2 Data for Aldoxorubicin for HIV-Related Kaposi's Sarcoma 4CytRx Announces Presentation of Interim Phase 2 Data for Aldoxorubicin for HIV-Related Kaposi's Sarcoma 5CytRx Announces Presentation of Interim Phase 2 Data for Aldoxorubicin for HIV-Related Kaposi's Sarcoma 6Convergence Trends See the Automotive Industry Integrate Health, Wellness and Wellbeing into Vehicles 2Convergence Trends See the Automotive Industry Integrate Health, Wellness and Wellbeing into Vehicles 3Convergence Trends See the Automotive Industry Integrate Health, Wellness and Wellbeing into Vehicles 4
... Ouchless ® Needle by BellaNovus Development Company ... Dr. Mariano Busso is the latest in a growing ... its use for cosmetic injections. Dr. Busso is on ... localized pain resulting from cosmetic injections. Ouchless ® ...
... a critical care company focused on developing and commercializing ... the U.S. Food and Drug Administration (FDA) has granted ... oxide (iNO) with the INOpulse® DS drug-delivery system as ... investigational new drug application (IND) for PAH was submitted ...
Cached Medicine Technology:New Ouchless® Needle Collection Announces Leading Dermatology Testimonial 2FDA Grants Orphan Drug Designation to Ikaria® For Use of Inhaled Nitric Oxide in Pulmonary Arterial Hypertension 2FDA Grants Orphan Drug Designation to Ikaria® For Use of Inhaled Nitric Oxide in Pulmonary Arterial Hypertension 3FDA Grants Orphan Drug Designation to Ikaria® For Use of Inhaled Nitric Oxide in Pulmonary Arterial Hypertension 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: